SASaliha Aksun

Saliha Aksun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saliha Aksun has a total of 197 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diet-Derived Trimethylamine N-Oxide (TMAO) Pathway Disruption in Patients with Concurrent Alcohol Use Disorder and Smokers Persists After Alcohol Detoxification

    by Betül Rabia Erdoğan, Zinnet Şevval Aksoyalp, Çağatay Hasip, Başak Bağcı, Saliha Aksun

    Background and Purpose: Trimethylamine N-oxide (TMAO), a gut-microbiota-derived metabolite, is associated with cardiometabolic diseases, and therapeutic strategies targeting TMAO reduction are gaining interest for disease management. This study aimed to compare serum TMAO levels in patients with alcohol use disorder (AUD) and smokers versus healthy controls, and to assess changes following medically supervised alcohol detoxification.Method: Demographic data, biochemical parameters, and serum TMAO levels were analyzed. These parameters were quantified in healthy controls and patients with AUD and smokers before and after alcohol detoxification.Results: The study included thirty-four healthy controls (six females and 28 males) and thirty-three patients (five females and 28 males) with AUD and smokers. At baseline, patients demonstrated significantly lower TMAO levels but higher levels of ferritin, CRP, AST, ALT, GGT, and MCV compared to healthy controls. Following detoxification, patients exhibited a further decrease in TMAO levels (p=0.024), alongside significant improvements in hepatic enzymes (AST and GGT) and ferritin levels (p

  • Open Access

    Clinical Significance of MTHFR C677T and A1298C Polymorphisms in Adult Patients with ALL and NHL

    by Hatice Demet Kiper Unal, Tugba Cetintepe, Roya Gasimli, Alev Garip Acar, Kemal Aygun, Serife Solmaz, Asli Subasioglu, Saliha Aksun, Bahriye Payzin

    Background/Objectives: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms may influence folate metabolism and DNA synthesis, potentially affecting disease characteristics and clinical outcomes in hematologic malignancies. This study investigated the associations of MTHFR C677T and A1298C polymorphisms with clinical features and survival outcomes in adult patients with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). Methods: A total of 92 adult patients with ALL or NHL treated with standard chemotherapy were retrospectively analyzed. MTHFR C677T and A1298C genotypes were determined using real-time polymerase chain reaction. Associations between genotypes and baseline clinical features, treatment response, toxicity, overall survival (OS), and progression-free survival (PFS) were examined. Results: The C677T heterozygous genotype was significantly associated with the presence of B symptoms (p = 0.027). No significant differences were observed across genotypes with respect to other baseline clinical features, treatment response, or treatment-related toxicity. In the overall cohort (ALL + NHL), OS and PFS did not differ significantly by C677T or A1298C genotypes. However, in the NHL cohort, carriers of the C677T variant demonstrated significantly shorter PFS (p = 0.048) and a non-significant trend toward lower OS. This association was also observed in the DLBCL subgroup for PFS (p = 0.043), with a similar non-significant trend observed for OS. Conclusions: Although MTHFR genotyping appears to have limited value for broad clinical stratification, the observed association between the C677T polymorphism and PFS in NHL—particularly in the DLBCL subgroup—suggests a potential subtype-specific relevance that warrants further validation in larger, disease-specific cohorts.


  • The Need to Include Pregabalin in Routine Substance Screening Panels to Detect Non-Therapeutic Use and Abuse

    by Saliha Aksun, Başak Bağci, Oğuz Karalar, Murat Aksun, Barış Karadaş, Faruk Yavuz, Aslı Tuğba Esen, Mert Üğe, Figen Narin

    Pregabalin, prescribed for various neurological and psychiatric conditions, has demonstrated increasing potential for abuse. Despite its psychoactive effects and growing misuse, pregabalin remains absent from standard urine drug screening panels in Türkiye. To assess the prevalence of pregabalin abuse through comprehensive biochemistry laboratory data and to underscore the necessity of including pregabalin in routine toxicological screening protocols. This retrospective study analyzed urine drug screening results from 2019 to 2024 obtained in a tertiary hospital's biochemistry laboratory. Analysis was performed using a validated liquid chromatography system coupled with a tandem mass spectrometry method, which included pregabalin, gabapentin, and over 140 other substances. Data were stratified by year, clinical department, and co-detected substances. Urine pregabalin concentrations were statistically compared between single-use and polydrug use groups using the Mann-Whitney U-test. Pregabalin was detected in 15%-18% of analyzed urine samples annually, sometimes exceeding methamphetamine detection rates. The majority of positive cases originated from probation services and the Alcohol and Substance Use Disorder Treatment Center outpatient clinics. Notably, urine samples with co-detected substances exhibited significantly higher pregabalin concentrations (P < .05). The most frequently co-used drugs were cannabis and methamphetamines. However, a significant subgroup used pregabalin as the sole psychoactive substance. These individuals would be misclassified as "negative" in routine screening panels that exclude pregabalin. To describe this diagnostic blind spot, the term "incomplete negativity" is proposed, referring to toxicology reports that falsely appear negative due to limited panel scope, not true drug abstinence. Pregabalin abuse remains under-recognized due to current technical and regulatory limitations. Inclusion of pregabalin in routine drug panels is both feasible and urgently needed. The concept of incomplete negativity, introduced in this study, underscores the need to revise national toxicology practices and expand screening panels to include pregabalin. A multidisciplinary approach involving clinical psychiatry, medical biochemistry, and public health authorities is crucial. Recognizing this diagnostic gap is essential for effective clinical and legal responses to substance use disorders.

  • Trimethylamine N-oxide as a potential prognostic biomarker for mortality in patients with COVID-19 disease

    by Zinnet Şevval Aksoyalp, Betül Rabia Erdoğan, Saliha Aksun, Melih Kaan Sözmen, Murat Aksun, Cüneyt Kemal Buharalıoğlu, Nagihan Altıncı-Karahan, Nergiz Hacer Turgut, Tijen Kaya-Temiz


  • Open Access

    Trends in pregabalin misuse and abuse: A 25-year bibliometric perspective

    by Sali̇ha Aksun, Karalar Oguz, Mert Üge, Berna Cafer

    Background: Originally classified among antiepileptic drugs, pregabalin has been prescribed for clinical conditions such as neuropathic pain, generalised anxiety disorder, and fibromyalgia. In recent years, accumulating evidence has highlighted its potential for misuse and abuse, particularly among individuals with a high prevalence of opioid dependence. This study aims to conduct a comprehensive bibliometric analysis of global research on pregabalin misuse and abuse, to identify key trends, influential contributors, and collaborative networks. Methods: Bibliometric design was employed using data retrieved from the Web of Science Core Collection database. The search was conducted in February 2025, and relevant publications were identified based on predefined inclusion and exclusion criteria. A total of 449 eligible records were exported and compiled for analysis. The bibliometric analysis was carried out using the bibliometrix R package and its Web-based interface Biblioshiny, both operating within the RStudio environment. Results: The analysis revealed a notable increase in scientific output on pregabalin misuse and dependence, particularly after 2010. The United States emerged as the most prolific and central country within the global collaboration network, followed by the United Kingdom, Germany, and France. Leading authors and institutions were concentrated in specific academic clusters. Keywords such as "abuse," "addiction," and "opioids" have shown an increasing trend since 2016. Conclusions: This study highlights the growing academic interest in the misuse and abuse potential of pregabalin, particularly over the past decade. The findings reveal a centralised research structure, with significant contributions from high-capacity countries such as the United States, the United Kingdom, and Germany. Emerging participation from developing countries, including Türkiye, underscores a broadening global awareness of the issue. The results emphasise the importance of interdisciplinary collaboration, policies, and the critical role of clinical laboratories in monitoring pregabalin-related risks.

  • Open Access

    Six SIGMA-based quality assessment of biochemical analytes: A comparative analysis of clinical laboratory improvement amendments 1988 and 2024 standards

    by Mert Üge, Saliha Aksun

    Background: Laboratories have a responsibility to produce accurate and reliable results to ensure patient safety and meet quality standards. Within the Six SIGMA quality management framework, various approaches may emerge depending on the total allowable error (TAE) limits defined by different standards. This study aimed to compare analyte SIGMA levels using CLIA 1988 and CLIA 2024 criteria, determine appropriate quality control procedures based on Westgard multirules, and identify potential sources of error using the Quality Goal Index. Methods: SIGMA values for 17 biochemical analytes were calculated based on internal and external quality control data using the formula (TEa - bias)/CV The Quality Goal Index (QGI) was determined using the formula bias/(1.5xCV). All analytes were evaluated at the Karabuk Public Health Laboratory between November 2024 and March 2025. Results: Amylase (Levels 1 and 2), total bilirubin (Level 1), high-density lipoprotein cholesterol (Levels 1 and 2), creatine kinase (Levels 1 and 2), and lactate dehydrogenase (Levels 1 and 2) demonstrated world-class SIGMA performance according to both CLIA 1988 and CLIA 2024 standards. However, a decline in SIGMA values was observed when calculated using the more stringent CLIA 2024 limits. Conclusions: The comparison of CLIA 1988 and CLIA 2024 standards demonstrated that stricter TEa limits can significantly impact the performance of SIGMA. While some analytes maintained world-class performance, others exhibited a notable decline, necessitating enhanced quality control measures. These findings emphasise the need for laboratories to periodically reassess test performance in light of evolving regulatory standards to ensure continued analytical reliability and patient safety.


  • Investigation Bisphenol A and Phthalate Levels in Idiopathic Hyperandrogenemia

    by Mert Üğe, Saliha Aksun, Mehmet Sercan Ertürk, Tuğba Öncel Van, Leyla Demir, Barış Önder Pamuk, Figen Narin

    Amaç: İdiyopatik hiperandrojenemi, kadınlarda hirsutizm belirtileri, artmış serum androjen düzeyleri, normal adet döngüsü ve normal yumurtalık morfolojisi ile seyreden bir hastalık olarak tanımlanır. Bu çalışmada, Bisfenol A ve mono-etilhekzil fitalat'ın bu hastalıkla ilişkisinin incelenmesi amaçlandı. Materyal ve Metod: Araştırmaya 18-45 yaş arası toplam 91 birey dahil edildi. Hasta grubunu, endokrin polikliniğine hirsutizm bulgusu ile başvuran ve androjen düzeyi yüksek olan 43 kadın; kontrol grubunu ise hirsutizm bulgusu ve herhangi bir ek hastalığı olmayan 48 sağlıklı kadın oluşturdu. Bisfenol A ve mono-etilhekzil fitalat düzeyleri idrarda sıvı kromatografi-kütle spektrometri yöntemiyle ölçüldü. Bulgular: Hasta grubunda idrar Bisfenol A düzeyleri, kontrol grubuna göre anlamlı olarak yüksek bulundu (1,6 ng/ml; 0,55 ng/ml, p=0,035). Mono-etilhekzil fitalat düzeyleri ise kontrol grubunda, hasta grubuna göre anlamlı olarak yüksek bulundu (1,81 ng/ml; 1,66 ng/ml, p=0,01). Lojistik regresyon analizinde odds oranları, BPA için 1,91 (%95 güven aralığı: 1,13-3,24; p<0,05), yaş için 0,91 (%95 güven aralığı: 0,81-1,01; p=0,09), fT3 için 18,74 (%95 güven aralığı: 3,86-90,85; p<0,05), prolaktin için 1,06 (%95 güven aralığı: 0,98-1,14; p=0,09) olarak bulundu. Sonuç: Hiperandrojenemi etiyolojisinde daha az sıklıkla yer alan bu grupta, endokrin bozucu kimyasalların etkisinin incelenmesi çalışmamızı özgün kılmaktadır. Hasta grubunda Bisfenol A idrar düzeyinin kontrol grubuna göre yüksek olması, idiyopatik hiperandrojenemililerde Bisfenol A'nın etkisini düşündürmektedir. Kontrol grubunda ise mono-etilhekzil fitalat düzeylerinin daha yüksek bulunması, daha fazla ftalat metabolitinin incelenmesi ve daha fazla çalışma yapılması gerektiğini düşündürmektedir.

  • Open Access

    False positive ecstasy (MDMA) urine drug screening test results due to bupropion use: A case report

    by Selin Acar Şahan, Barış KARADAŞ, Semra Aydin Akfirat, Nihat Aydemi̇r, Saliha Aksun, Yusuf Kaplan

    This case report is about a false positive ecstasy (MDMA) result in the urine substance abuse screening analysis of a person using the antidepressant drugs bupropion and sertraline with a therapeutic indication. Urine drug and stimulant screening analysis of a 25-year-old male patient who is history of bupropion (300 mg/day) and sertraline (100 mg/day) use, followed in the Amatem polyclinic due to the probation law, was performed with Syva® Emit® II Plus kits and immunoassay method. In order to confirm the ecstasy test, which was positive in the screening analysis, the substance analysis was repeated on the same sample with the gas chromatography sequential mass spectrometry (GC-MS) method and ecstasy was not detected in the confirmation analysis. At the same time, the presence of bupropion and sertraline patient declared to use, was confirmed with the LC-MS-Iontrap device. In conclusion, with this case example, we wanted to highlight the potential interaction of bupropion with the Syva® Emit® II Plus urine ecstasy screening tests, which could lead to false positive results. When positive ecstasy values are detected in the urine samples analyzed with the immunoassay method in patients using bupropion, the final decision should be made after a confirmatory analysis.


  • Laboratuvarımızda Çalışılan Prenatal Tarama Testlerinde Ölçüm Belirsizliği

    by Leyla Demir, Saliha Aksun

    Amaç: Ölçüm belirsizliği hem bir yöntemin amaca uygunluğu hem de bir laboratuvarda elde edilen analitik sonuçların güvenilirliği için önemli bir göstergedir. ISO 15189 gibi akreditasyon süreçleri de laboratuvarlardan ölçüm belirsizliği için belirlenmiş bir yöntemleri olmasını ve istendiğinde ölçüm belirsizliği sonuçlarını sağlamasını beklemektedir. Bu çalışmada amacımız birinci ve ikinci trimester prenatal tarama testlerinde kullanılan biyokimya parametrelerinin ölçüm belirsizliğini hesaplayıp bu değerleri total izin verilebilir hata oranları ile karşılaştırmaktır. Gereç ve Yöntem: Laboratuvarımızda prenatal tarama testlerinde kullanılan gebelikle ilişkili plazma protein-A (PAPP-A), serbest beta insan koryonik gonadotropini (sß-hCG), alfa feto protein (AFP), insan koryonik gonadotropini (HCG) ve unkonjuge estriol (uE3) parametreleri için ölçüm belirsizliği hesaplandı, Nordest kılavuzunda yer alan Avrupa akreditasyon rehberi ve Eurolab teknik raporu ISO 21748 rehberinden faydalanarak hesaplamalar yapıldı. Bu hesaplamalarda iç kalite kontrol ve dış kalite kontrol sonuçları kullanıldı. Bulgular: Ölçüm belirsizlik değerleri AFP için %16.4, sβ-hCG için %17.04, HCG için %27.84, PAPP-A için %18.54 ve uE3 için %22.52 olarak bulundu. Çalışmamızda en yüksek ölçüm belirsizliği HCG ve uE3 parametreleri için bulunurken en düşük ölçüm belirsizliği ise AFP için bulundu. Sonuç: Laboratuvarımızda prenatal tarama testlerine ait biyokimyasal parametrelerin ölçüm belirsizlikleri hesaplanmıştır. HCG, PAPP-A ve uE3 testlerinin ölçüm belirsizliği yüksek bulunmuştur, Özellikle risk açısından eşik değere yakın prenatal tarama testlerinde ölçüm belirsizliğinin dikkate alınarak sonuçların yorumlanması önemlidir.

  • Open Access

    Optimization of enzyme-linked immunosorbent assay kit protocol to detect trimethylamine N-oxide levels in humans

    by Zinnet Sevval Aksoyalp, Betül Rabia Erdoğan, Saliha Aksun

    The serum level of trimethylamine N-oxide (TMAO), a gut microbiota metabolite associated with diabetes, cancer, inflammatory and neurological diseases, can be determined by the micro-enzyme-linked immunosorbent assay (ELISA) method. However, we had problems obtaining accurate standard curves with the original kit protocol from Bioassay Technology Laboratory. We aimed to acquire proper standard curves by modifying the kit protocol in this study. First, we evaluated the human TMAO ELISA kit protocols and other human ELISA kits. We maintained the incubation times longer and increased the wash cycle. Moreover, we incubated the standards containing biotinylated antibody in the wells alone. Then we washed the wells and added streptavidin-HRP for the second incubation step. The data of original and modified ELISA kit protocol were analyzed with Student's t-test. We measured higher absorbance with lower standard solution concentration in experiments that followed the original kit protocol. After investigating other human TMAO ELISA kits, we noticed that the SunRed Biotechnology Company and MyBioSource companies suggested similar protocols to the Bioassay Technology Laboratory company. The ELK Biotechnology ELISA protocol was different from others. However, since there is no biotinylated antibody in the standard solution in the ELK biotechnology kit, we changed some steps by examining other human ELISA protocols from different companies. After performing the modified protocol, we found that the absorbances of the standard solutions were consistent with their concentrations, and we obtained an accurate standard curve. Higher R2 values and lower absolute difference of standard concentrations were found in the modified kit protocol. The human TMAO ELISA protocol, which we modified in this study, will enable researchers to obtain more reliable results and prevent them from failing time and resources.